These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 15760720

  • 1. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M, Nordström K.
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [Abstract] [Full Text] [Related]

  • 2. Russia through the prism of the world biopharmaceutical market.
    Bairamashvili DI, Rabinovich ML.
    Biotechnol J; 2007 Jul; 2(7):801-17. PubMed ID: 17615600
    [Abstract] [Full Text] [Related]

  • 3. Chinese biotech hamstrung by production issues.
    Jia H.
    Nat Biotechnol; 2007 Feb; 25(2):147-8. PubMed ID: 17287733
    [No Abstract] [Full Text] [Related]

  • 4. Market access for biopharmaceuticals: new challenges.
    Simon F.
    Health Aff (Millwood); 2006 Feb; 25(5):1363-70. PubMed ID: 16966734
    [Abstract] [Full Text] [Related]

  • 5. Biopharmaceuticals in China.
    Hu X, Ma Q, Zhang S.
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [Abstract] [Full Text] [Related]

  • 6. Growing pains for biopharmaceuticals.
    Ashton G.
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract] [Full Text] [Related]

  • 7. Deal watch: Biopharma deal-making in 2015: changing the pharma landscape.
    Micklus A, Muntner S.
    Nat Rev Drug Discov; 2016 Feb; 15(2):78-9. PubMed ID: 26837586
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biosimilars: opportunity or cause for concern?
    Roger SD, Mikhail A.
    J Pharm Pharm Sci; 2007 Feb; 10(3):405-10. PubMed ID: 17727803
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD, Califf RM, Schulman KA.
    Health Aff (Millwood); 2006 Feb; 25(5):1309-17. PubMed ID: 16966727
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Overcoming further challenges in the pharma/biotech industry: 2007 update.
    Graul AI, Cruces E, Revel L, Serradell N, Rosa E.
    Drug News Perspect; 2008 Feb; 21(1):44-58. PubMed ID: 18301809
    [Abstract] [Full Text] [Related]

  • 16. Overcoming the challenges in the pharma/biotech industry.
    Graul AI, Prous JR.
    Drug News Perspect; 2007 Feb; 20(1):57-68. PubMed ID: 17332900
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Regulatory perspectives from Japan - comparability of biopharmaceuticals.
    Kawanishi T.
    Biologicals; 2006 Mar; 34(1):65-8. PubMed ID: 16330220
    [Abstract] [Full Text] [Related]

  • 19. Innovation in biotechnology: current and future states.
    Woollett GR.
    Clin Pharmacol Ther; 2012 Jan; 91(1):17-20. PubMed ID: 22179626
    [Abstract] [Full Text] [Related]

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.